The latest biotech news

News and Trends 17 Aug 2022

Researchers invited to apply for DNA synthesized by Evonetix’s platform

An early access program for semiconductor synthesized DNA has been opened by UK-based gene synthetic biology company, Evonetix. Evonetix’s DNA synthesis capability brings together semiconductor chip design and proprietary, thermally controlled synthesis chemistry, integral to the company’s future gene synthesis platforms. Silicon chip The company’s proprietary process utilizes a silicon chip to control the synthesis […]

August 17, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Aug 2022

Ryvu Therapeutics bags €22M from EIB to work on new cancer treatments

The European Investment Bank (EIB) is providing €22 million ($22.4 million) in financing to Ryvu Therapeutics, a Polish clinical-stage drug discovery and development company focusing on novel small molecule therapies that address unmet medical needs in oncology. The funding is being provided under the EIB’s venture debt instrument, which is tailored to the specific financing […]

August 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 17 Aug 2022

New partnership delivers clinically proven products and manufacturing processes for advanced therapies

AGC Biologics has announced its partnership with supplier of human mesenchymal stem/stromal cells (hMSCs), RoosterBio Inc. The partnership, the companies say creates an end-to-end solution for the development and production of hMSCs and exosome therapeutics using RoosterBio’s well-established cell and media products and process development services together with AGC’s cell and gene therapy manufacturing capabilities. […]

August 17, 2022 - 3 minutesmins - By Liza Laws

News and Trends 17 Aug 2022

Sanofi drops amcenestrant clinical development program

Sanofi says it is discontinuing the global clinical development program of amcenestrant, an investigational oral selective estrogen receptor degrader (SERD). The decision was based on the outcome of an interim analysis of the phase 3 AMEERA-5 trial evaluating amcenestrant in combination with palbociclib compared with letrozole in combination with palbociclib in patients with estrogen receptor-positive […]

August 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Viridian reports positive news from ongoing trial for patients with Thyroid Eye Disease

Patients with active thyroid eye disease (TED) could benefit from rapid and significant improvements after positive data emerged from a clinical trial. Viridian Therapeutics made the announcement yesterday (August 15) that the 10mg/kg cohort in its ongoing phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody TED – an autoimmune disease where the body’s own immune […]

August 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Aug 2022

Programmable medicines company Senda Biosciences closes $123M series C financing

U.S.-headquartered Senda Biosciences, Inc. has completed $123 million in series C financing, bringing its total funding raised to date to $266 million. Flagship Pioneering, which founded Senda, participated along with new investors, including the Samsung Life Science Fund, Qatar Investment Authority (QIA), Bluwave Capital, and Stage 1 Ventures. Also participating in the financing are current […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Merck puts up to $37B into Orna Therapeutics circular RNA collaboration

Merck, also known as MSD outside the U.S. and Canada, and Orna Therapeutics, a biotech company working on a new investigational class of engineered circular RNA (oRNA) therapies, are to collaborate on discovering, developing, and commercializing multiple programs, including vaccines and therapeutics, in the areas of infectious diseases and oncology. Under the terms of the […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

Patient dosed in phase 1 trial evaluating ATG-018 treatment

News and Trends 16 Aug 2022

Patient dosed in phase 1 trial evaluating treatment for those with tumors and malignancies

The first patient has been dosed in a phase 1 trial evaluating a monotherapy treatment in people with advanced solid tumors and hematologic malignancies in Australia. Antengene Corporation Ltd., is running the ATRIUM trial, a phase 1 multi-center, open-label, dose-finding study of monotherapy ATG-018. Safety and tolerability of ATG-018 The primary objective of the study […]

August 16, 2022 - 3 minutesmins - By Liza Laws

ADC Therapeutics announces $175M loan from Owl Rock

News and Trends 16 Aug 2022

ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock

ADC Therapeutics has announced a series of major strategic transactions involving hundreds of millions of dollars allowing it to advance its lead candidate and pipeline drugs. The Swiss company has entered into a new $175 million senior secured loan with certain funds of Owl Rock – a division of Blue Owl Capital, Inc. and funds […]

August 16, 2022 - 3 minutesmins - By Liza Laws

PBC clinical trials: Gannex doses first patient

News and Trends 16 Aug 2022

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

A study looking at a treatment for primary biliary cholangitis (PBC) has this month (August) enrolled 12 patients and is expected to be completed by the start of this year’s fourth quarter. Gannex Pharma Co., Ltd., owned by Ascletis Pharma Inc., announced yesterday (August 15) that it had finished its first dosing in the […]

August 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Aug 2022

Pneumagen embarks on phase 2 proof of concept influenza study

Biotech company Pneumagen says the first person has been dosed in its phase 2 controlled human infection challenge study. Its product, Neumifil, is an intranasal, broad-spectrum antiviral treatment to prevent or, if infected, reduce and manage, viral respiratory tract infections. The phase 2 trial is a single center, randomized, double-blinded, placebo-controlled study evaluating two dose […]

August 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Inhibrx chondrosarcoma treatment gets EC orphan medicinal product designation

Following a positive opinion from the European Medicines Agency (EMA), the European Commission (EC) has granted orphan medicinal product designation to Inhibrx, Inc. for INBRX-109 for the treatment of chondrosarcoma. “We are highly optimistic about the potential of INBRX-109 in chondrosarcoma to address a high unmet medical need,” said Inhibrx CEO, Mark Lappe. “The positive […]

August 16, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Researchers invited to apply for DNA synthesized by Evonetix’s platform

Ryvu Therapeutics bags €22M from EIB to work on new cancer treatments

New partnership delivers clinically proven products and manufacturing processes for advanced therapies

Sanofi drops amcenestrant clinical development program

Viridian reports positive news from ongoing trial for patients with Thyroid Eye Disease

Programmable medicines company Senda Biosciences closes $123M series C financing

Merck puts up to $37B into Orna Therapeutics circular RNA collaboration

Patient dosed in phase 1 trial evaluating treatment for those with tumors and malignancies

ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

Pneumagen embarks on phase 2 proof of concept influenza study

Inhibrx chondrosarcoma treatment gets EC orphan medicinal product designation

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!